Discover and measure proteins in tissue - In-depth protein
analysis in formalin-fixed paraffin-embedded (FFPE) tissue
using mass spectrometry.
Identify and measure biomarkers of disease progression
and drug response - Use tissue collections with detailed patient
clinical histories.
Study protein expression in tissue at the cellular
level - Conduct proteomic analysis on specific
laser microdissected cellular features.
Tissue microproteomic collaborations -
Access our technologies and research capability in collaborations
and research service agreements.
Liquid Tissue® is a registered trademark
of Expression Pathology Inc. US and international
patents pending for Liquid Tissue® and DIRECTOR™ products. Our
Terms and Conditions apply. The Liquid Tissue® MS
is sold under a limited
license with commercial use restrictions. For further
details please contact us.
Expression
Pathology Inc. (EPI) is a leader in tissue microproteomics. Our technologies
make possible mass spec protein analysis of formalin-fixed tissue,
enabling discovery, validation and routine measurement of protein
biomarkers related to clinical outcomes. Our near-term mission is
to offer breakthrough research tools and collaborations to improve
drug and diagnostic development and for basic research. Our proprietary
technologies also provide the foundation for a whole new platform
of tissue diagnostic tests currently under development.
The Liquid
Tissue® MS protocol prepares FFPE samples
for mass spec analysis. Complete solubilization
captures the entire protein content. Mass
spec friendly. Requires only 30,000 cells
for multiple mass spectrometry analyses.
The Director™ Laser Microdissection
Slides provide the fastest, easiest and most accurate
way to collect specific cellular features
from tissue sections. Engineered for use
with existing Leica LMD and PALM Zeiss
laser microdissection system.
news sidebar
News & Events
NextGen
Sciences and Expression Pathology to provide protein biomarker
discovery and measurement in tissue, June 30, 2008. (press
release)
Quantitative
Proteomic Analysis of Formalin Fixed Paraffin Embedded Oral HPV Lesions
from HIV Patients, The Open Proteomics Journal, 2008, 1, 40-45,
June 15, 2008. (abstract)
Two
of Expression Pathology's key patents have issued covering
its DIRECTOR™ Slide technology for improved tissue laser microdissection Gaithersburg,
MD. May 19, 2008: (press release).
Expression
Pathology Obtains SBIR to Identify Protein Biomarkers of Breast
Cancer
Metastasis, May 15, 2008 (press
release).
ASMS,
Denver, June 1-5. (link)
Booth 21. Register for our tissue proteomic luncheon
seminar on Wednesday, June 4.
American
Association of Cancer Research, San
Diego, April 12-16. (link)
Booth 2428. See three posters using our technology; discovery
of endometrial cancer markers (write-up),
metastasis marker in melanoma (abstract),
protein biomarkers relating to metastasis and disease progression
in lung cancer (abstract).
A Molecular Portrait of Head and Neck Cancer Progression,
Clin. Cancer Res., Feb. 15, 2008 (abstract)
Expression Pathology Aids Research in Identifying Biomarkers
of Lung Cancer Metastasis and Survival, Feb. 19, 2008 (article
and press release)
Expression Pathology Obtains Maryland Funding to Develop
Breast Cancer Test, Feb. 6, 2008(press
release)
